An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

NCT02529930 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

High Grade Cervical Intraepithelial Neoplasia

Interventions

BIOLOGICAL: VB10.16 Immunotherapy (DNA vaccine)

Sponsor

Nykode Therapeutics ASA

Collaborators

[object Object]
[object Object]